GTx, Inc. (NASDAQ:GTXI) issued its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.25), Bloomberg Earnings reports.

GTx (NASDAQ GTXI) opened at $11.64 on Thursday. GTx has a 1-year low of $2.73 and a 1-year high of $12.96.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another site, it was copied illegally and reposted in violation of United States and international trademark and copyright laws. The correct version of this news story can be viewed at

Separately, Stifel Nicolaus began coverage on shares of GTx in a report on Thursday, November 9th. They set a “buy” rating for the company.

GTx Company Profile

GTx, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs).

Earnings History for GTx (NASDAQ:GTXI)

Receive News & Stock Ratings for GTx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTx Inc. and related stocks with our FREE daily email newsletter.